Kevin Laliberte is VP at Dova Pharmaceuticals, Inc. (DOVA). They have made 3 open-market trades across 1 company since 2017, most recently 2019-11-12.
CIK 0001709417
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $105K since 2017, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| DOVA | 4,761 | $133K |
Shares reported on the most recent Form 4, priced at the 2019-10-02 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DOVA | SELL | 2019-09-30 | 2019-10-02 | $28.00 | $103K | +0.2% | +0.7% | N/A |
| DOVA | SELL | 2019-09-25 | 2019-09-27 | $20.00 | $62K | +0.5% | +1.0% | N/A |
| DOVA | SELL · 10b5-1 | 2019-07-31 | 2019-08-01 | $15.97 | $22K | +0.9% | -6.0% | +76.5% |
| DOVA | SELL · 10b5-1 | 2019-07-01 | 2019-07-02 | $14.17 | $17K | -2.7% | -4.4% | +69.4% |
| DOVA | BUY | 2017-07-05 | 2017-07-07 | $17.00 | $105K | -7.6% | -25.6% | +6.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.